Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1962-1968

  Dotan, Zohar A ^a   Bianco Jr , Fernando J ^a   Rabbani, Farhang ^a   Eastham, James A ^a   Fearn, Paul ^a   Scher, Howard I ^a   Kelly, Kevin W ^a   Chen, Hui Ni ^a   Schöder, Heiko ^a   Hricak, Hedvig ^a   Scardino, Peter T ^a   Kattan, Michael W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN THERAPY; ARTICLE; BONE SCINTISCANNING; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; KINETICS; MAJOR CLINICAL STUDY; NOMOGRAM; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; BLOOD; BONE; FACTUAL DATABASE; MALE; METASTASIS; PREDICTION AND FORECASTING; PROBABILITY; PROSTATE TUMOR; SCINTISCANNING;

BONE AND BONES; DATABASES, FACTUAL; HUMANS; MALE; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 20144374797     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.058     Document Type: Article

References (24)

1. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781-789, 2002
2. Hull GW, Rabbani F, Abbas F, et al: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167:528-534, 2002
3. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001
4. Dillioglugil O, Leibman BD, Kattan MW, et al: Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 50:93-99, 1997
5. Han M, Partin AW, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523, 2003
6. Roberts SG, Blute ML, Bergstralh EJ, et al: PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76:576-581, 2001
7. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
8. Ferguson JK, Oesterling JE, Lange PH, et al: Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol Clin North Am 21:677-685, 1994
9. Nudell DM, Wefer AE, Hricak H, et al: Imaging for recurrent prostate cancer. Radiol Clin North Am 38:213-229, 2000
10. Terris MK, Klonecke AS, McDougall IR, et al: Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 32:1713-1717, 1991
11. Oesterling JE, Martin SK, Bergstralh EJ, et al: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269:57-60, 1993
12. Chybowski FM, Keller JJ, Bergstralh EJ, et al: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 145:313-318, 1991
13. Lee CT, Oesterling JE: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24:389-394, 1997
14. Cher ML, Bianco FJ Jr, Lam JS, et al: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160:1387-1391, 1998
15. Kane CJ, Amling CL, Johnstone PA, et al: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607-611, 2003
16. Ross PL, Scardino PT, Kattan MW: A catalog of prostate cancer nomograms. J Urol 165: 1562-1568, 2001
17. Ohori M, Wheeler TM, Dunn JK, et al: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152:1714-1720, 1994
18. Ohori M, Scardino PT: Localized prostate cancer. Curr Probl Surg 39:833-957, 2002
19. Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 163:1632-1642, 2000
20. Ornstein DK, Colberg JW, Virgo KS, et al: Evaluation and management of men whose radical prostatectomies failed: Results of an international survey. Urology 52:1047-1054, 1998
21. Miller PD, Eardley I, Kirby RS: Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 70:295-298, 1992
22. D'Amico AV, Chen MH, Roehl KA, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2004
23. Scher HI, Heller G: Clinical states in prostate cancer: Toward a dynamic model of disease progression. Urology 55:323-327, 2000
24. Di Blasio CJ, Rhee AC, Cho D, et al: Predicting clinical end points: Treatment nomograms in prostate cancer. Semin Oncol 30:567-586, 2003